|
|
|
| Effect of Erlotinib and Pemetrexed on Late Stage of NSCLC Patients with Failure of First-line Standard Chemotherapy |
| HE Zhi-hui, LU Yan-da, HUANG Fen,et al |
| Hainan MedicalCollegeFirstAffiliated Hospital,570102 |
|
|
|
|
Abstract 【Objective】To analyze the efficacy of erlotinib and pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) who failed first-line standard chemotherapy regimen. 【Methods】A total of 90 patients with advanced NSCLC were divided into two groups according to the order of admission. Group A was treated with oral erlotinib 150mg/d and group B was treated with pemetrexed 500mg/m2 intravenously. The clinical effects of the two groups were analyzed. 【Results】The total effective rate and disease control rate between the two groups were not significantly different (P>0.05). There were no significant differences in the levels of carbohydrate antigen 50 (CA50) and cytokeratin 19 fragment (CYFRA21-1) between the two groups before treatment (P>0.05). After treatment, the levels of CA50 andCYFRA21-1 in each group were lower than those before treatment (P<0.05). However, there were no significant differences between the two groups after treatment (P>0.05). The overall quality of life in group A was better than that in group B (P<0.05). The main adverse reactions in group A were rash and diarrhea, while in group B, bone marrow suppression and gastrointestinal reaction were the main side effects. There was significant difference in the incidence of adverse reactions between the two groups (P<0.05). 【Conclusion】The efficacy of erlotinib and pemetrexide in the treatment of advanced NSCLC with failure of the first-line standard chemotherapy regimen is similar. They both can reduce the levels of tumor markers. Erlotinib has obvious advantage in improving the quality of life.
|
|
Received: 09 January 2019
|
|
|
|
|
|
[1] 张卉,张树才.非小细胞肺癌EGFR基因靶向治疗研究进展[J].中国肺癌杂志,2017,20(1):61-65.
[2] 杨阳,王凡.厄洛替尼联合贝伐单抗治疗对老年晚期非小细胞肺癌患者免疫功能及血清肿瘤标志物的影响及作用机制[J].中国老年学杂志,2018,38(5):1098-1100.
[3] 任洁,芦兰,程春来,等.培美曲塞在老年晚期非小细胞肺癌姑息性化疗中的作用[J].中国老年学杂志,2017,37(9):2195-2196.
[4] 刘畅,李枫,王莉,等.天佛参口服液联合GP 方案治疗老年晚期非小细胞肺癌的近期疗效观察[J].癌症进展,2017,15(3):294-296.
[5] Laslett NF, Park S, Masters GA,et al.Phase Ⅱ study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer[J].Cancer Med,2018, 7(7):2969-2973.
[6] 宁凯笛,周恬,项永晶,等.厄洛替尼联合氯喹对EGFR野生型非小细胞肺癌增殖、凋亡及自噬相关蛋白表达的影响[J].山东医药,2018,58(34):13-16.
[7] 马建欣,马永新,刘建伟,等.厄洛替尼在化疗失败表皮生长因子受体突变型老年非小细胞肺癌患者中应用[J].临床军医杂志,2018,46(7):820-821.
[8] 殷金兰,李莹,陈金梅,等.4项肿瘤标志物检测在晚期非小细胞肺癌治疗中的意义[J].国际检验医学杂志,2017,38(14):1985-1987.
[9] 季禹乔,孙明忠,朱晖,等.血清miRNA-21与肿瘤标志物CEA、CYFRA21-1、NSE对早期非小细胞肺癌的诊断价值[J].中国实验诊断学,2017,21(4):576-581. |
|
|
|
2019, Vol. 36 
